Solid Biosciences Free Cash Flow (FCF) History (SLDB)
Solid Biosciences reported −$157.4M in free cash flow for fiscal 2025, a decrease of $56.8M from the previous fiscal year.
View full Solid Biosciences company overviewSolid Biosciences free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$157.4M | −$56.8M | — | — |
| 2024 | 2024-12-31 | −$100.7M | −$5.0M | — | — |
| 2023 | 2023-12-31 | −$95.7M | $5.3M | — | — |
| 2022 | 2022-12-31 | −$101.0M | −$21.9M | — | −1247.74% |
| 2021 | 2021-12-31 | −$79.0M | −$21.5M | — | −580.36% |
| 2020 | 2020-12-31 | −$57.5M | $39.6M | — | — |
| 2019 | 2019-12-31 | −$97.1M | −$19.1M | — | — |
| 2018 | 2018-12-31 | −$78.0M | −$32.5M | — | — |
| 2017 | 2017-12-31 | −$45.5M | −$25.0M | — | — |
| 2016 | 2016-12-31 | −$20.5M | — | — | — |
Solid Biosciences quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$52.7M | −$14.9M | — | — |
| Q1 2026 | 2026-03-31 | −$47.4M | −$15.4M | — | — |
| Q4 2025 | 2025-12-31 | −$54.1M | −$24.3M | — | — |
| Q3 2025 | 2025-09-30 | −$33.6M | −$9.8M | — | — |
| Q2 2025 | 2025-06-30 | −$37.8M | −$16.0M | — | — |
| Q1 2025 | 2025-03-31 | −$32.0M | −$6.6M | — | — |
| Q4 2024 | 2024-12-31 | −$29.8M | −$8.9M | — | — |
| Q3 2024 | 2024-09-30 | −$23.7M | −$5.4M | — | — |
| Q2 2024 | 2024-06-30 | −$21.8M | $6.2M | — | — |
| Q1 2024 | 2024-03-31 | −$25.3M | $3.2M | — | — |
| Q4 2023 | 2023-12-31 | −$20.9M | $14.4M | — | — |
| Q3 2023 | 2023-09-30 | −$18.3M | $3.0M | — | — |
| Q2 2023 | 2023-06-30 | −$28.0M | −$11.0M | — | — |
| Q1 2023 | 2023-03-31 | −$28.5M | −$1.1M | — | — |
| Q4 2022 | 2022-12-31 | −$35.3M | −$13.8M | — | — |
| Q3 2022 | 2022-09-30 | −$21.3M | −$2.6M | — | — |
| Q2 2022 | 2022-06-30 | −$17.0M | $435,000 | — | — |
| Q1 2022 | 2022-03-31 | −$27.4M | −$6.0M | — | — |
| Q4 2021 | 2021-12-31 | −$21.5M | −$22.8M | — | — |
| Q3 2021 | 2021-09-30 | −$18.7M | −$3.0M | — | — |
| Q2 2021 | 2021-06-30 | −$17.4M | −$4.3M | — | — |
| Q1 2021 | 2021-03-31 | −$21.4M | $8.6M | — | — |
| Q4 2020 | 2020-12-31 | $1.2M | $23.1M | — | — |
| Q3 2020 | 2020-09-30 | −$15.6M | $4.2M | — | — |
| Q2 2020 | 2020-06-30 | −$13.1M | $14.3M | — | — |
| Q1 2020 | 2020-03-31 | −$30.0M | −$2.1M | — | — |
| Q4 2019 | 2019-12-31 | −$21.9M | $951,000 | — | — |
| Q3 2019 | 2019-09-30 | −$19.9M | −$2.5M | — | — |
| Q2 2019 | 2019-06-30 | −$27.4M | −$7.9M | — | — |
| Q1 2019 | 2019-03-31 | −$27.9M | −$9.7M | — | — |
| Q4 2018 | 2018-12-31 | −$22.8M | −$8.5M | — | — |
| Q3 2018 | 2018-09-30 | −$17.4M | −$6.3M | — | — |
| Q2 2018 | 2018-06-30 | −$19.5M | −$9.9M | — | — |
| Q1 2018 | 2018-03-31 | −$18.2M | −$7.7M | — | — |
| Q4 2017 | 2017-12-31 | −$14.3M | — | — | — |
| Q3 2017 | 2017-09-30 | −$11.1M | — | — | — |
| Q2 2017 | 2017-06-30 | −$9.6M | — | — | — |
| Q1 2017 | 2017-03-31 | −$10.4M | — | — | — |
Solid Biosciences free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$57.5M to −$157.4M, a net decrease of $99.9M. Solid Biosciences's latest reported quarter, Q2 2026, generated −$52.7M in free cash flow, a decrease of $14.9M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Solid Biosciences source filings ↗